BioNTech SE (BNTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
BioNTech SE
Address
An der Goldgrube 12
Mainz, RP 55131
Germany
Phone
49 6131 9084 0
Sector
Healthcare
Industry
Biotechnology
Employees
7807
First IPO Date
October 10, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Ugur Sahin | Co-Founder, Chief Executive Officer & Chair of the Management Board | 1.19M | 1965 |
| Ozlem Tureci | Co-Founder, Chief Medical Officer & Member of Management Board | 952,575 | 1967 |
| Sierk Pötting | MD, Chief Operating Officer & Member of Management Board | 983,158 | 1973 |
| James Timothy Patrick Ryan | Chief Legal & Business Officer and Member of the Management Board | 1.01M | 1975 |
| Annemarie Hanekamp | Chief Commercial Officer & Member of Management Board | 1.02M | 1980 |
| Ramon Zapata-Gomez | Chief Financial Officer & Member of Management Board | 1.16M | 1974 |
| Jasmina Alatovic | Vice President Corporate Communications | 0 | N/A |
| Douglas Maffei | Vice President of Strategy & Investor Relations | 0 | N/A |
| Kylie Jimenez | Chief People Officer & Member of Management Board | 0 | 1976 |
| Lisa Birringer | Senior Vice President of Global Financial Reporting & Accounting | 0 | N/A |
Description
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
